IgA Nephropathy Drugs Market is projected to witness lucrative growth by reaching up to US$ 436.4 million by 2030 | Calliditas Therapeutics AB, Travere Therapeutics, Inc., Omeros Corporation

Global IgA nephropathy drugs market reached US$ 120.1 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 436.4 million by 2030, exhibiting a CAGR of 18.1% during the forecast period (2024-2031).

IgA Nephropathy Drugs Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/iga-nephropathy-drugs-market?sg

The IgA nephropathy drugs market is witnessing significant growth, driven by rising product launches, advancing technologies, and increasing research and development efforts. IgA nephropathy is an autoimmune disease that affects the kidneys, leading to inflammation and damage as antibody clumps, including Immunoglobulin A (IgA), accumulate in the glomeruli small blood vessels responsible for blood filtration. This damage results in the leakage of blood and protein into the urine.

The market is expanding due to the growing adoption of IgA nephropathy drugs, fueled by the increasing availability of treatment options, a rising incidence of nephropathy, and a surge in product approvals. Additionally, North America is experiencing strong demand, driven by rapid advancements in the field. Key players such as Novartis AG, Chinook Therapeutics, and Everest Medicines are actively contributing to market growth.

List of the Key Players in the IgA Nephropathy Drugs Market: Calliditas Therapeutics AB, Travere Therapeutics, Inc., Omeros Corporation, Vera Therapeutics, MorphoSys AG, Otsuka Pharmaceutical, Alembic Pharmaceuticals Limited, Everest Medicines, Novartis AG and Alexion Pharmaceuticals, Inc.

Industry Development:

On August 1, 2023, the Phase 3 NefIgArd study's China open-label extension (cOLE) has seen the last patient enrolled, according to Everest Medicines, a biopharmaceutical firm specializing in the research, production, and marketing of novel drugs and vaccines. All eligible participants who have successfully completed the NefIgArd study are eligible for an additional 9 months of Nefecon treatment as part of the cOLE study, which will assess the effectiveness and safety of prolonged and repeated Nefecon medication in patients having IgA nephropathy (IgAN).

On March 12, 2023, positive topline results from the global, double-blind, randomized, placebo-controlled third phase clinical trial NefIgArd, which compared the effectiveness of Nefecon (TARPEYO/Kinpeygo (budesonide) extended-release capsules) to a placebo in patients having primary IgA nephropathy (IgAN), were released by Calliditas Therapeutics AB. The estimated glomerular filtration rate (eGFR) was the primary endpoint of the trial, and Nefecon demonstrated a highly statistically significant advantage over placebo across the two-year period of 9 months of treatment using Nefecon or placebo and 15 months of follow-up off drug.

Growth Forecast Projected:

The Global IgA Nephropathy Drugs Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global IgA Nephropathy Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/iga-nephropathy-drugs-market?sg

Segment Covered in the IgA Nephropathy Drugs Market:

By Type (Primary IgA Nephropathy, Secondary IgA Nephropathy)

By Drug Type (Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Immunosuppressants, Omega-3 Fatty Acids, Diuretics, Others)

By Route of Administration (Oral, Parental, Others)

By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Regional Analysis for IgA Nephropathy Drugs Market:

The regional analysis of the IgA Nephropathy Drugs Market covers key regions including North America, Europe, Asia Pacific Middle East and Africa and South America. The North America with a focus on the U.S., Canada, and Mexico; Europe, highlighting major countries like the U.K., Germany, France, and Italy, along with other nations in the region; Asia-Pacific, covering India, China, Japan, South Korea, and Australia, among others; South America, with emphasis on Colombia, Brazil, and Argentina; and the Middle East & Africa, which includes Saudi Arabia, the U.A.E., South Africa, and other countries. This comprehensive regional breakdown helps identify unique market trends and growth opportunities specific to each area.

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

View Our Report: https://www.datamintelligence.com/research-report/iga-nephropathy-drugs-market?sg

People Also Ask:

➠ What is the global sales, production, consumption, import, and export value of the IgA Nephropathy Drugs market?

➠ Who are the leading manufacturers in the global IgA Nephropathy Drugs industry? What is their operational status in terms of capacity, production, sales, pricing, costs, gross margin, and revenue?

➠ What opportunities and challenges do vendors in the global IgA Nephropathy Drugs industry face?

➠ Which applications, end-users, or product types are expected to see growth? What is the market share for each type and application?

➠ What are the key factors and limitations affecting the growth of the IgA Nephropathy Drugs market?

➠ What are the various sales, marketing, and distribution channels in the global industry?

Browse More Reports:

Nephrology Drugs Market - https://www.datamintelligence.com/research-report/nephrology-drugs-market?sg

Diabetic Nephropathy Market - https://www.datamintelligence.com/research-report/diabetic-nephropathy-market?sg

Neuropathy Screening and Diagnosis Market - https://www.datamintelligence.com/research-report/neuropathy-screening-and-diagnosis-market?sg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.